Search research articles
Contact Us
Filters
Showing results (1-10 of 267) with videos related to
Page
of 27
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 21, 2015
Current therapies and their indications for the Philadelphia-negative myeloproliferative neoplasms
Jean-Jacques Kiladjian
The Lancet. Haematology
|
June 27, 2020
Long-term efficacy and safety of ruxolitinib in polycythaemia vera - Authors' reply
Jean-Jacques Kiladjian
La Revue Du Praticien
|
December 13, 2005
[Diagnosis and treatment of primary thrombocythemia]
Jean-Jacques Kiladjian
The Lancet. Haematology
|
March 15, 2017
Long-term treatment with interferon alfa for myeloproliferative neoplasms
Jean-Jacques Kiladjian
Hematology. American Society of Hematology. Education Program
|
December 13, 2012
The spectrum of JAK2-positive myeloproliferative neoplasms
Jean-Jacques Kiladjian
Hematology. American Society of Hematology. Education Program
|
December 7, 2024
Pegylated interferon: the who, why, and how
Jean-Jacques Kiladjian
Therapie
|
December 13, 2021
The challenge of targets and drug discovery using large-scale screening approaches in onco-hematology
Lina Benajiba, Jean-Jacques Kiladjian
Bulletin Du Cancer
|
August 7, 2016
[Not Available]
Juliette Soret, Jean-Jacques Kiladjian
American Journal of Hematology
|
March 4, 2023
Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategies
Jean-Jacques Kiladjian, Bruno Cassinat
Blood
|
October 16, 2012
Live and let (MPN cells) die!
Bruno Cassinat, Jean-Jacques Kiladjian
Page
of 27
Search research articles
Search
Showing results (1-10 of 267) with videos related to
Sort By:
Page
of 27
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 21, 2015
Current therapies and their indications for the Philadelphia-negative myeloproliferative neoplasms
Jean-Jacques Kiladjian
The Lancet. Haematology
|
June 27, 2020
Long-term efficacy and safety of ruxolitinib in polycythaemia vera - Authors' reply
Jean-Jacques Kiladjian
La Revue Du Praticien
|
December 13, 2005
[Diagnosis and treatment of primary thrombocythemia]
Jean-Jacques Kiladjian
The Lancet. Haematology
|
March 15, 2017
Long-term treatment with interferon alfa for myeloproliferative neoplasms
Jean-Jacques Kiladjian
Hematology. American Society of Hematology. Education Program
|
December 13, 2012
The spectrum of JAK2-positive myeloproliferative neoplasms
Jean-Jacques Kiladjian
Hematology. American Society of Hematology. Education Program
|
December 7, 2024
Pegylated interferon: the who, why, and how
Jean-Jacques Kiladjian
Therapie
|
December 13, 2021
The challenge of targets and drug discovery using large-scale screening approaches in onco-hematology
Lina Benajiba, Jean-Jacques Kiladjian
Bulletin Du Cancer
|
August 7, 2016
[Not Available]
Juliette Soret, Jean-Jacques Kiladjian
American Journal of Hematology
|
March 4, 2023
Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategies
Jean-Jacques Kiladjian, Bruno Cassinat
Blood
|
October 16, 2012
Live and let (MPN cells) die!
Bruno Cassinat, Jean-Jacques Kiladjian
Page
of 27